

# Assessment of light transmission aggregometry on the routine coagulation analyzer Siemens CS-2500 using CEmarked agonists from Hyphen Biomed

V.-E. BRETT¹, B. POUGAULT², A. GUY¹, S. CASTET³, Y. HUGUENIN³, C. JAMES¹, M. FIORE¹.⁴ . ¹University Hospital of Bordeaux, Laboratory of Hematology, Pessac, France, ²Siemens Healthcare, Saint-Denis, France,

University Hospital of Bordeaux, Haemophilia Center, Bordeaux, France,
University Hospital of Bordeaux, Reference Center for Platelet Disorders, Bordeaux, France





Dr M. Fiore, Laboratoire d'hématologie, Centre de Référence des Pathologies Plaquettaires Constitutionnelles, CHU de Bordeaux, Hôpital Cardiologique, Pessac, France. Tel: +33 (0)5 57 65 64 78; Fax: +33 (0)5 57 65 68 45; E-mail:

### INTRODUCTION

Light transmission aggregometry (LTA) is still considered as the "gold standard" for platelet function assessment but, as a completely manual technology, it is labour intensive. This challenge can be overcome by performing platelet aggregometry in an automated method on a routine coagulation analyzer.

#### AIM


To compare and correlate results obtained from a traditional manual LTA solution using platelet agonists provided from different manufacturers and realized in our Referent Center with a complete solution including the CS-2500 (Siemens) optimized automated system and CE-marked agonist reagents from Hyphen Biomed.

#### **METHOD**

- Platelet rich plasma from patients with suspected platelet disorders, von Willebrand disease or antiplatelet therapy have been assessed using a wide range of agonist concentrations: ADP (0.5- 10 µM), collagen (2 mg/µL), ristocetin (0.625-1.2 mg/mL) or arachidonic acid (1 mM).
- The APACT-4004 aggregometer (Elitech, France) was used as the reference instrument with platelet agonists provided from different manufacturers.
- We evaluated the CS-2500 analyzer using dedicated software and CE-marked agonists from Hyphen Biomed.
- Results were expressed as Maximal Platelet Aggregation and correlation between the CS-2500 and the APACT-4004 was analyzed using the Passing and Bablok regression test and the Bland-Altman analysis.

## **RESULTS**

- Between October and December 2017, platelet aggregometry studies were performed in 49 samples (35 samples concerned patients with suspected platelet disorders, 6 samples were RIPA and 8 samples corresponded to antiplatelet therapy tailoring).
- Maximal aggregation response with ADP (0.5-10 μM), collagen (2 mg.mL<sup>-1</sup>), ristocetin (1.2 mg.mL<sup>-1</sup>) and arachidonic acid (1 mM) agonists showed significant correlation between the two aggregometers (p<0.01) (Figure 1).
- We observed a more variable response using low doses of ADP ( $\leq 5 \mu M$ ).
- We also noted discrepancies with low dose of ristocetin (0.625 mg.mL<sup>-1</sup>), showing excessive paradoxical agglutination with the CS-2500.
- Bland and Altman plots showed that 95% of the differences were located within acceptable range with most of the agonists, allowing to conclude that the two compared devices could be considered as consistent (Figure 2).
- Eight samples had platelet count in PRP below 150x109 L-1 (range from 34x109 L<sup>-1</sup> to 142x10<sup>9</sup> L<sup>-1</sup>). In most of these cases, platelet maximal aggregations were consistent between the two systems (Table I).
- One sample of PRP was tested 5 times with 5 µM ADP, showing 1.5% intra-serial imprecision (CV%) of maximal intensity of platelet aggregation assessed with the CS-2500 instrument compared to 6.6% with the APACT-4004.






Figure 1. Correlations between the APACT-4004 and the CS-2500 using the Passing and Bablok regression test (blue lines: fitted regression lines; dotted lines: regression line confidence bands).




Figure 2. Bland and Altman plots between the APACT-4004 and the CS-2500 systems.

## CONCLUSIONS

Comparison of platelet aggregometry on the manual APACT-4004 with the automated CS-2500 platform showed good agreement between the two platforms in a clinical setting. Implementation of LTA in this fully-automated routine coagulation analyzer system should make platelet function testing more widely available and could have the capacity for a high sample throughput.